Association of Pan Immune-Inflammation Value with Long Term Outcomes of Acute Decompensated Heart Failure
Arquivos Brasileiros de Cardiologia · 2024 · 121 (6)
DOI: 10.36660/abc.20230817i ↗Kurz gefasst
Fachartikel in der Zeitschrift Arquivos Brasileiros de Cardiologia, 2024. Verfasst von Bektas Murat und 6 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Although there have been significant improvements in the treatment of heart failure (HF) in recent decades, its prognosis remains poor. Although there are many biomarkers that can help predict the prognosis of patients with HF, there is a need for simpler, cheaper, and more easily available biomarkers.
Objective
To evaluate the predictive value of pan-immune-inflammation value (PIV) in patients with acute decompensated HF.
Methods
We analyzed 409 patients with HF with reduced ejection fraction who were hospitalized for acute decompensated HF. Patients were divided into 3 groups according to tertiles of PIV: tertile 1 (PIV < 357.25), tertile 2 (PIV ≥ 357.25 and < 834.55), and tertile 3 (PIV ≥ 834.55). P values < 0.05 were considered statistically significant. Kaplan-Meier curves and Cox proportional hazards regression models were used to evaluate the association between PIV and all-cause mortality. The primary outcome was 5-year all-cause mortality, and the secondary outcomes were in-hospital 30 days,, 180-day, and 1-year all-cause mortality.
Results
We showed that higher PIV value was associated with both primary and secondary outcomes. The Kaplan-Meier curve showed that patients with higher PIV values had an increased risk of short- and long-term all-cause mortality (log-rank p < 0.001). In the multivariate analysis, PIV was identified as an independent predictor of long-term all-cause mortality in patients with acute decompensated HF, and we observed a 1.96-fold increase in the hazard of an event (odds ratio: 1.96, 95% confidence interval: 1.330 to 2.908, p = 0.001).
Conclusions
Our study showed that the novel biomarker PIV can be used as a predictor of prognosis in patients with acute decompensated HF.
Zitieren
APA
Murat, B., Murat, S., Altınbas, M. E., Yalvac, H. E., Durmaz, F. E., Mert, K. U., & Cavusoglu, Y. (2024). Association of Pan Immune-Inflammation Value with Long Term Outcomes of Acute Decompensated Heart Failure. Arquivos Brasileiros de Cardiologia, 121(6). https://doi.org/10.36660/abc.20230817i
Vancouver
Murat B, Murat S, Altınbas ME, Yalvac HE, Durmaz FE, Mert KU, et al. Association of Pan Immune-Inflammation Value with Long Term Outcomes of Acute Decompensated Heart Failure. Arquivos Brasileiros de Cardiologia. 2024;121(6). doi:10.36660/abc.20230817i
BibTeX
@article{Murat2024,
author = {Murat, Bektas and Murat, Selda and Altınbas, Mehmet Eren and Yalvac, Halit Emre and Durmaz, Fatih Enes and Mert, Kadir Ugur and Cavusoglu, Yüksel},
title = {Association of Pan Immune-Inflammation Value with Long Term Outcomes of Acute Decompensated Heart Failure},
journal = {Arquivos Brasileiros de Cardiologia},
year = {2024},
volume = {121},
number = {6},
doi = {10.36660/abc.20230817i}
}
EUVIMED